1. A 52-year-old woman with paroxysmal AF and previously confirmed structurally normal heart has been on flecainide 100 mg twice daily with metoprolol for 18 months with excellent rhythm control and no side effects. She now presents with an acute anterior STEMI and undergoes successful primary PCI. Post-PCI, her LVEF is 44% with an anterior wall motion abnormality. Which of the following best represents the correct management of her flecainide regimen going forward?
A) Continue flecainide at the current dose; the drug was appropriately prescribed for a structurally normal heart and the acute MI does not change the risk-benefit calculation because the CAST contraindication applies only to patients who were started on Class Ic agents after an MI, not to patients who developed an MI while already established on the drug
B) Continue flecainide temporarily but plan to discontinue at her 3-month post-MI follow-up visit; the CAST contraindication becomes relevant only after the myocardium has healed and scar tissue is fully established, at which point the heterogeneous re-entrant substrate that creates proarrhythmic risk is present
C) Discontinue flecainide immediately; the development of ischemic structural heart disease from the acute MI ; manifesting as new wall motion abnormality and reduced LVEF ; has transformed this patient from an appropriate Class Ic candidate to one in whom flecainide is absolutely contraindicated by the CAST principle; the drug must be stopped regardless of prior appropriateness, and an alternative rhythm control strategy discussed after her acute MI management is stabilized
D) Reduce the flecainide dose by 50 percent and repeat echocardiography in six weeks; if the LVEF recovers above 50 percent with no wall motion abnormality, flecainide can be resumed at full dose because the reversibility of post-ischemic stunning means the structural substrate may resolve
E) Continue flecainide and add amiodarone for enhanced antiarrhythmic protection during the acute post-MI period; the combination provides complementary sodium and potassium channel blockade that is specifically beneficial in the peri-infarct electrophysiological milieu
ANSWER: C
Rationale:
The CAST contraindication is not based on when the drug was started but on the patient's current structural status. This patient was appropriately prescribed flecainide when her heart was structurally normal ; the drug was correctly chosen for that clinical context. However, the acute anterior MI has fundamentally changed her myocardial substrate: she now has ischemic structural heart disease with a wall motion abnormality and reduced LVEF of 44%, creating the heterogeneous peri-infarct myocardium in which Class Ic slow-recovery sodium channel blockade generates new re-entrant circuits rather than suppressing existing ones. The CAST trial demonstrated this mechanism in exactly this population. Flecainide must be discontinued immediately ; the drug that was safe 48 hours ago is now contraindicated by her changed clinical status. The prior 18 months of successful therapy is clinically irrelevant to this determination. Alternative rhythm control strategies in a post-MI patient with reduced LVEF are limited: amiodarone is the pharmacological option, and implantable cardioverter-defibrillator (ICD) evaluation is indicated given her LVEF of 44% at 40 days post-MI.
Option A: Option A is incorrect: the CAST contraindication applies based on structural status, not on when the drug was initiated; a patient who develops MI while on flecainide must stop the drug just as firmly as one who would be denied it at initiation.
Option B: Option B is incorrect: waiting three months is clinically unacceptable; the ischemic substrate is present immediately after MI and the proarrhythmic risk is highest in the early post-MI period; delaying discontinuation exposes the patient to the maximum period of risk.
Option D: Option D is incorrect: echocardiographic recovery does not negate the CAST contraindication in a patient with documented ischemic structural disease; even if the LVEF normalizes, the presence of ischemic scar tissue maintains the structural substrate for proarrhythmia.
Option E: Option E is incorrect: adding amiodarone to flecainide compounds risk without resolving the fundamental contraindication; flecainide must be stopped first, and amiodarone can then be considered as the alternative.
2. A 71-year-old man with obstructive hypertrophic cardiomyopathy (HOCM) and CrCl of 32 mL/min is started on disopyramide 150 mg three times daily combined with metoprolol for symptomatic left ventricular outflow tract (LVOT) obstruction. Two weeks later he presents with urinary retention requiring catheterization, worsening dyspnea, and a fall in blood pressure from 128/78 to 98/62 mmHg. His LVOT gradient has actually decreased from 64 mmHg to 38 mmHg. Which of the following best explains this clinical picture?
A) Disopyramide undergoes significant renal elimination, with approximately 55 percent excreted as unchanged drug in the urine; in a patient with CrCl of 32 mL/min, disopyramide and its active metabolite accumulate to supratherapeutic concentrations; elevated disopyramide levels amplify both its desired effect (negative inotropy reducing the LVOT gradient) and its adverse effects ; specifically its pronounced negative inotropy causing hemodynamic compromise and its antimuscarinic properties causing urinary retention; dose reduction is required
B) The clinical deterioration reflects metoprolol toxicity from pharmacokinetic interaction; disopyramide inhibits cytochrome P450 2D6 (CYP2D6), raising metoprolol plasma concentrations to toxic levels; the excessive beta-blockade has caused the hypotension and urinary retention through beta-2 receptor blockade in the detrusor muscle, while the LVOT gradient reduction reflects the combined negative chronotropic effect of the two drugs
C) The urinary retention and hemodynamic compromise reflect a paradoxical vagolytic crisis from disopyramide's antimuscarinic properties in a patient with autonomic neuropathy from longstanding hypertension; the CrCl of 32 mL/min reflects end-organ damage from hypertension rather than a pharmacokinetic concern requiring dose adjustment
D) The clinical picture reflects excessive metoprolol-induced bradycardia rather than disopyramide toxicity; at heart rates below 50 beats per minute, disopyramide's negative inotropy is dramatically amplified through a heart rate-dependent pharmacodynamic interaction; the LVOT gradient reduction confirms that both drugs are working but at excessive intensity
E) The findings are expected and acceptable therapeutic effects in a patient with HOCM; the hemodynamic compromise from excessive LVOT gradient reduction is a known dose-limiting effect requiring temporary outpatient diuretic therapy rather than dose adjustment of disopyramide, as reducing the dose would allow the gradient to return
ANSWER: A
Rationale:
Disopyramide has a pharmacokinetic profile that makes renal impairment clinically important: approximately 55 percent of the drug is excreted unchanged in the urine, making renal clearance a major elimination route. In a patient with CrCl of 32 mL/min, disopyramide clearance is substantially reduced and the drug accumulates to concentrations exceeding the therapeutic range. This accumulation simultaneously amplifies all of disopyramide's pharmacological effects. The therapeutic effect (negative inotropy reducing the LVOT gradient) is amplified ; explaining the greater-than-expected gradient reduction from 64 to 38 mmHg. The adverse effects are simultaneously amplified: the pronounced negative inotropy that is beneficial in HOCM becomes hemodynamically excessive at supratherapeutic concentrations, producing hypotension and worsening dyspnea. The antimuscarinic (anticholinergic) properties, which produce urinary retention, dry mouth, and constipation at therapeutic doses, are dramatically amplified at toxic concentrations ; producing the urinary retention requiring catheterization. Management requires dose reduction (typically starting at 100 mg twice daily or less in significant renal impairment) with clinical reassessment.
Option B: Option B is incorrect: disopyramide does not inhibit CYP2D6; this interaction describes propafenone or quinidine; urinary retention from beta-2 blockade in the detrusor is not a recognized mechanism of metoprolol toxicity.
Option C: Option C is incorrect: the pharmacokinetic concern with disopyramide's renal elimination in CrCl 32 mL/min is real and clinically significant; dismissing it as irrelevant autonomic neuropathy is incorrect.
Option D: Option D is incorrect: disopyramide does not exhibit heart rate-dependent amplification of negative inotropy through pharmacodynamic interaction with metoprolol; the accumulation is pharmacokinetic from impaired renal elimination.
Option E: Option E is incorrect: hemodynamic compromise from excessive LVOT gradient reduction with hypotension (98/62 mmHg) and worsening dyspnea requires drug dose reduction, not outpatient diuresis; the clinical picture represents toxicity.
3. A 58-year-old man with alcoholic cirrhosis (Child-Pugh class B) develops sustained VT requiring intravenous lidocaine. A resident proposes starting the standard infusion protocol of 1 to 4 mg/min after a loading bolus of 1.5 mg/kg. An attending physician intervenes and recommends a substantially reduced infusion rate. Which of the following correctly explains the pharmacokinetic basis for this recommendation?
A) Lidocaine in cirrhosis requires a higher infusion rate than standard because portal hypertension diverts drug away from the hepatic sinusoids through portosystemic shunts before it can be metabolized, reducing the effective hepatic drug exposure; the systemic concentration falls faster than expected, requiring higher infusion rates to maintain therapeutic levels
B) The recommendation is unnecessary; lidocaine undergoes renal elimination as unchanged drug in cirrhotic patients because hepatic metabolic enzymes are uniformly downregulated; renal clearance becomes the primary elimination route, and as long as renal function is normal, standard dosing applies without modification
C) Lidocaine requires dose reduction in cirrhosis because the reduced plasma albumin in cirrhosis decreases protein binding, raising the free lidocaine fraction and producing toxicity at lower total plasma concentrations; a 30 percent reduction in infusion rate corrects for the altered protein binding
D) Lidocaine requires dose reduction because cirrhosis increases the volume of distribution through ascites and peripheral edema; the larger volume of distribution means the loading bolus achieves lower peak concentrations, but the larger distribution space also slows elimination, requiring a proportionally lower maintenance infusion to prevent accumulation
E) Lidocaine has a high hepatic extraction ratio, meaning its clearance is normally limited by hepatic blood flow; in cirrhosis, both hepatic blood flow and intrinsic hepatic metabolic capacity (due to hepatocyte loss and reduced CYP enzyme expression) are substantially reduced; the combination of reduced flow and reduced intrinsic clearance dramatically impairs lidocaine elimination, causing drug accumulation at standard infusion rates and producing CNS and cardiac toxicity at much lower doses; the infusion rate should be reduced by approximately 50 percent and CNS monitoring must be intensified
ANSWER: E
Rationale:
Lidocaine's pharmacokinetics in hepatic disease are determined by its high hepatic extraction ratio ; a measure of how efficiently the liver removes drug from the blood during a single pass. High extraction ratio drugs are primarily dependent on hepatic blood flow for their clearance: if blood flows through the liver quickly, more drug is cleared per unit time. In cirrhosis, lidocaine clearance is impaired through two parallel mechanisms. First, hepatic blood flow is reduced ; portal hypertension and the hemodynamic changes of cirrhosis reduce the effective hepatic perfusion. Second, the intrinsic metabolic capacity of the hepatocytes themselves is reduced ; hepatocyte loss, fibrosis, and reduced CYP enzyme activity (primarily CYP3A4 (cytochrome P450 3A4) and CYP1A2 (cytochrome P450 1A2)) expression impair the liver's ability to metabolize lidocaine even when blood flow is adequate. Both factors together produce a dramatic reduction in lidocaine clearance ; sometimes by 50 percent or more compared with normal hepatic function. At standard infusion rates, lidocaine accumulates rapidly and CNS toxicity (circumoral numbness, tinnitus, seizures) and cardiac toxicity develop at unexpectedly low total doses. The infusion rate should be substantially reduced and the patient monitored closely.
Option A: Option A is incorrect: portosystemic shunting actually allows drug to bypass hepatic metabolism and reach the systemic circulation unchanged, which would increase systemic concentrations ; not decrease them; this is precisely why oral drugs with high first-pass metabolism have increased bioavailability in cirrhosis.
Option B: Option B is incorrect: lidocaine undergoes hepatic metabolism (not renal elimination as unchanged drug) as its primary elimination route even in cirrhosis; renal function does not compensate for impaired hepatic lidocaine clearance.
Option C: Option C is incorrect: while cirrhosis does reduce albumin levels, lidocaine binds primarily to alpha-1 acid glycoprotein (AAG), not albumin; AAG levels are not consistently reduced in cirrhosis; the primary pharmacokinetic concern is clearance impairment, not protein binding alteration.
Option D: Option D is incorrect: while the volume of distribution may be altered in cirrhosis from ascites, the dominant pharmacokinetic concern requiring infusion rate reduction is impaired clearance from reduced hepatic blood flow and reduced intrinsic enzymatic capacity ; not volume of distribution changes.
4. A 48-year-old woman with well-controlled idiopathic systemic lupus erythematosus (SLE) on hydroxychloroquine develops symptomatic sustained ventricular tachycardia requiring a Class Ia antiarrhythmic. Her nephrologist and rheumatologist are both consulted. Which of the following best explains the most important agent-specific consideration within the Class Ia subgroup for this patient?
A) Quinidine is contraindicated in patients with SLE because its alpha-adrenergic blocking properties cause vasodilation that worsens the lupus nephritis-associated hypertension; disopyramide is the preferred Class Ia agent because its anticholinergic properties counteract the cholinergic excess that drives SLE flares
B) Procainamide should be avoided in this patient with established idiopathic SLE; procainamide is the Class Ia agent most strongly associated with drug-induced lupus-like syndrome (DILS), and in a patient with pre-existing SLE, procainamide's immunogenic hydroxylamine metabolites could exacerbate the underlying autoimmune process, DILS would be clinically indistinguishable from a lupus flare complicating disease management, and the established diagnosis of idiopathic SLE is a strong relative contraindication; quinidine or disopyramide are the preferred Class Ia alternatives
C) Disopyramide is contraindicated in SLE because its anticholinergic properties inhibit the acetylcholine-mediated regulatory T-cell function that suppresses SLE autoimmunity; loss of this cholinergic immunosuppression would produce a dramatic SLE flare within days of drug initiation
D) All three Class Ia agents (quinidine, procainamide, disopyramide) are equally contraindicated in SLE because they all share the immunogenic hydroxylamine metabolite pathway that triggers autoimmune responses; the distinction between DILS and SLE exacerbation cannot be made with any of these agents, requiring selection of a Class III agent instead
E) The Class Ia agent choice does not require modification for SLE; all three agents have equal rates of autoimmune adverse effects in patients with underlying SLE, and the selection should be based purely on cardiac pharmacology (quinidine preferred for its broad efficacy), with rheumatological monitoring added regardless of which agent is chosen
ANSWER: B
Rationale:
Among the three Class Ia agents, procainamide has a uniquely high risk of drug-induced lupus-like syndrome (DILS) ; developing antinuclear antibody (ANA) positivity in 50 to 80 percent of patients on chronic therapy and clinical DILS symptoms in 20 to 30 percent. The mechanism involves reactive hydroxylamine metabolites formed from procainamide's N-oxidation pathway, which modify nuclear protein antigens and trigger an autoimmune response. In a patient with established idiopathic SLE, prescribing procainamide creates compounding clinical problems: first, procainamide's immunogenic metabolites could potentially exacerbate the underlying autoimmune disease; second and critically, if DILS develops, it produces arthralgia, pleuritis, pericarditis, and ANA positivity that are clinically indistinguishable from an SLE flare, making disease attribution impossible and management extremely difficult. Established idiopathic SLE is therefore a strong relative contraindication to procainamide. Quinidine and disopyramide do not carry the same DILS risk profile and are the preferred Class Ia alternatives when a Class Ia agent is clinically necessary in this patient.
Option A: Option A is incorrect: quinidine's alpha-adrenergic blocking properties causing vasodilation do not represent a contraindication in SLE; lupus nephritis-associated hypertension is not worsened by vasodilation; this reasoning is pharmacologically incorrect.
Option C: Option C is incorrect: disopyramide's anticholinergic properties do not inhibit regulatory T-cell function through acetylcholine receptors in any established immunological mechanism; this represents a fabricated pharmacological interaction.
Option D: Option D is incorrect: the DILS risk is specifically associated with procainamide through its hydroxylamine metabolites; quinidine and disopyramide do not share this metabolic pathway or DILS risk profile; they are safer alternatives in SLE patients.
Option E: Option E is incorrect: the three Class Ia agents are not equally associated with autoimmune adverse effects in SLE; procainamide carries substantially greater risk and this distinction is clinically meaningful and well-established.
5. A 74-year-old man with paroxysmal AF, no structural heart disease, and mild chronic kidney disease (CrCl 52 mL/min) is started on flecainide 100 mg twice daily for rhythm control. He has been on digoxin 0.125 mg daily for rate control (serum digoxin level 0.9 ng/mL before starting flecainide). Two weeks after starting flecainide, he presents with nausea, visual disturbance, and bidirectional ventricular tachycardia on his ECG. His serum digoxin level is 2.8 ng/mL. Which of the following best explains this clinical deterioration?
A) Flecainide inhibits cytochrome P450 3A4 (CYP3A4), which is responsible for the hepatic metabolism of digoxin; reduced digoxin clearance has raised the plasma digoxin concentration from 0.9 to 2.8 ng/mL, producing the classic features of digoxin toxicity including nausea, visual changes, and bidirectional VT
B) Flecainide's sodium channel blockade in the renal tubule impairs the active secretion of digoxin into the tubular lumen, reducing renal digoxin clearance by approximately 50 percent and raising plasma digoxin concentrations to toxic levels; this interaction is pharmacodynamic rather than pharmacokinetic and requires permanent discontinuation of both drugs
C) The bidirectional VT and elevated digoxin level reflect flecainide-induced proarrhythmia in this patient who has occult structural heart disease; flecainide has converted subclinical paroxysmal VT into sustained bidirectional VT, and the apparent digoxin elevation is a laboratory artifact from flecainide cross-reacting with the digoxin immunoassay
D) Flecainide reduces renal tubular secretion of digoxin through inhibition of P-glycoprotein (P-gp) transport in the renal tubular epithelium, raising serum digoxin concentrations by approximately 15 to 25 percent on average; in this patient with already reduced renal function (CrCl 52 mL/min) and borderline digoxin levels, this pharmacokinetic interaction has pushed the digoxin concentration to toxic levels (2.8 ng/mL); the digoxin dose must be reduced and the level rechecked; this interaction is well-established and should be anticipated when initiating flecainide in digoxin-treated patients
E) The interaction is pharmacodynamic rather than pharmacokinetic; flecainide's sodium channel blockade sensitizes the myocardium to digoxin's pro-automaticity effects by reducing the resting membrane potential in Purkinje cells, allowing digoxin's toxic triggered activity to manifest at lower digoxin plasma concentrations; the measured digoxin level of 2.8 ng/mL overestimates true myocardial digoxin exposure
ANSWER: D
Rationale:
Flecainide has a clinically significant interaction with digoxin through inhibition of P-glycoprotein (P-gp), an efflux transporter expressed in renal tubular epithelial cells that normally secretes digoxin into the tubular lumen as part of its renal elimination. When flecainide inhibits P-gp in the renal tubule, digoxin secretion is reduced, renal clearance falls, and plasma digoxin concentrations rise. The magnitude of this interaction is typically 15 to 25 percent increase in serum digoxin levels. In this patient, several factors conspired to produce severe digoxin toxicity: his baseline CrCl of 52 mL/min already represents reduced renal function with lower-than-normal digoxin clearance; his pre-flecainide digoxin level of 0.9 ng/mL was in the therapeutic range but not far below the toxic threshold; and the P-gp inhibition by flecainide reduced clearance further. Management requires immediate digoxin dose reduction ; typically by 15 to 25 percent ; and close monitoring of levels. This interaction should be anticipated when starting flecainide in any digoxin-treated patient, with a plan to recheck the digoxin level within two weeks.
Option A: Option A is incorrect: digoxin is not metabolized by CYP3A4 in a clinically significant manner; digoxin undergoes minimal hepatic metabolism and is primarily renally eliminated; flecainide does not inhibit CYP3A4 in a clinically significant way.
Option B: Option B is incorrect: flecainide does not directly block sodium channels in renal tubular cells to impair digoxin secretion; the mechanism is P-glycoprotein inhibition, not sodium channel blockade; the interaction is pharmacokinetic, not pharmacodynamic; discontinuation of both drugs is not required.
Option C: Option C is incorrect: this patient has no structural heart disease and flecainide-induced proarrhythmia in structurally normal myocardium is uncommon; the digoxin level is genuinely elevated and the clinical presentation (nausea, visual changes, bidirectional VT) is a classic digoxin toxicity syndrome.
Option E: Option E is incorrect: the pharmacodynamic sensitization mechanism described is not the established explanation for this interaction; the digoxin level of 2.8 ng/mL genuinely reflects elevated digoxin concentrations from reduced P-gp-mediated renal secretion.
6. A 55-year-old man with congenital long QT syndrome type 3 (LQT3) has a prior inferior myocardial infarction from three years ago (LVEF 46%, small inferior scar on MRI). He is experiencing recurrent syncopal episodes despite maximum-dose beta-blocker therapy, with QTc consistently above 510 ms. His electrophysiologist proposes adding mexiletine. A colleague raises concern that any Class I antiarrhythmic is contraindicated in a patient with prior MI. Which of the following correctly adjudicates this clinical disagreement?
A) The colleague is correct; all Class I antiarrhythmic agents ; including Class Ib agents such as mexiletine ; are contraindicated in any patient with prior myocardial infarction and structural heart disease based on the CAST trial principle, which applies uniformly across all three Class I subclasses
B) The colleague is partially correct; mexiletine can be used in prior MI but only if the LVEF exceeds 50 percent; in this patient with LVEF of 46%, the risk of mexiletine-induced proarrhythmia from Class Ib sodium channel block in the peri-infarct zone outweighs the benefit of QTc reduction, and the drug is relatively contraindicated
C) The colleague is incorrect; the CAST contraindication applies specifically to Class Ic agents (flecainide, encainide, propafenone) in structural heart disease ; not to Class Ib agents; mexiletine (Class Ib) has fast-recovery kinetics and preferential activity in ischemic and depolarized tissue and is routinely used for VT suppression in structural heart disease; additionally, mexiletine is specifically and mechanistically indicated for LQT3 through INa,late blockade; the mechanistic benefit and acceptable safety profile in structural heart disease make mexiletine appropriate in this patient
D) The colleague is correct in principle but the clinical urgency overrides the contraindication; mexiletine can be used as a temporary bridge in life-threatening LQT3 with recurrent syncope despite maximum beta-blockade, but must be discontinued within six months and replaced with a non-Class I agent; ICD implantation should be completed during the bridge period
E) The colleague is incorrect but for the wrong reason; mexiletine is acceptable not because it is Class Ib but because LQT3 patients have paradoxically upregulated sodium channel expression that neutralizes the proarrhythmic sodium channel blocking effect; the drug acts through a gain-of-function corrective mechanism that is specific to SCN5A gain-of-function mutations and does not apply to normal myocardium
ANSWER: C
Rationale:
This clinical scenario requires precise subclass differentiation within the Class I antiarrhythmic framework. The CAST trial enrolled post-MI patients with ventricular premature beats and demonstrated that Class Ic agents ; flecainide and encainide ; increased arrhythmic death and total mortality. The mechanism is the slow-recovery kinetics of Class Ic agents creating new re-entrant circuits in heterogeneous ischemic myocardium. Class Ib agents (mexiletine, lidocaine) have fast-recovery kinetics ; their block dissipates fully during normal diastolic intervals ; and they do not create the same conduction heterogeneity in ischemic tissue. In fact, Class Ib agents have preferential activity in ischemic and depolarized myocardium and are routinely used for VT suppression in structural heart disease without the CAST contraindication. Mexiletine is specifically indicated for LQT3 through its blockade of the persistent late sodium current (INa,late) generated by the gain-of-function SCN5A mutation. The combination of an appropriate safety profile in structural heart disease and specific mechanistic efficacy for LQT3 makes mexiletine the correct choice for this patient.
Option A: Option A is incorrect: the CAST contraindication does not apply to all Class I subclasses; it specifically applies to Class Ic agents in structural heart disease; Class Ib agents are not contraindicated and are routinely used in this setting.
Option B: Option B is incorrect: there is no LVEF threshold (above or below 50%) that defines the boundary of Class Ib safety in structural heart disease; the CAST principle applies to Class Ic agents regardless of LVEF, and Class Ib agents are not subject to this ejection fraction threshold.
Option D: Option D is incorrect: mexiletine in LQT3 with structural heart disease is not a temporary bridge requiring discontinuation within six months; this is not an established clinical guideline; if the drug is effective and safe, it can be continued; additionally framing it as a contraindication being overridden by urgency mischaracterizes the pharmacology.
Option E: Option E is incorrect: LQT3 patients do not have paradoxically upregulated sodium channel expression that neutralizes proarrhythmic risk; mexiletine's safety in structural heart disease is based on its Class Ib kinetics, not on a gain-of-function corrective mechanism.
7. A 69-year-old man with CrCl of 35 mL/min is admitted with hemodynamically stable sustained ventricular tachycardia. The team elects to use intravenous procainamide for acute pharmacological termination. Which of the following best describes the specific monitoring and management consideration that is uniquely important in this patient compared with a patient with normal renal function?
A) NAPA (N-acetylprocainamide), the principal active metabolite of procainamide formed by hepatic N-acetyltransferase 2 (NAT2), is eliminated almost entirely by renal excretion; in a patient with CrCl of 35 mL/min, NAPA clearance is substantially impaired and NAPA will accumulate during and after the procainamide infusion; NAPA's Class III IKr-blocking activity will progressively prolong the QTc even after the procainamide infusion is stopped; the QTc must be monitored closely, NAPA levels measured alongside procainamide levels, and the duration of infusion limited to the minimum necessary for VT termination; an alternative agent should be considered if longer-term antiarrhythmic therapy is required
B) Procainamide itself (not NAPA) accumulates in renal failure because the parent drug undergoes significant renal elimination; the parent drug's sodium channel blocking activity causes progressive QRS widening that requires ECG monitoring every 30 minutes; if the QRS exceeds 25 percent above baseline, the infusion must be stopped regardless of clinical response
C) The primary concern in renal impairment is the increased risk of procainamide-induced drug-induced lupus-like syndrome (DILS) from accumulation of the parent compound; slow acetylators with renal impairment accumulate hydroxylamine metabolites that cannot be cleared renally and trigger autoimmune responses within 48 to 72 hours of infusion; prophylactic hydroxychloroquine should be given concurrently
D) Procainamide requires dose reduction in renal impairment because its volume of distribution is increased by the uremic retention of protein binding competitors; the elevated free fraction of procainamide produces enhanced sodium channel blockade requiring a 50 percent reduction in loading dose before any infusion is started
E) No specific modification is required for acute IV procainamide administration in a patient with CrCl of 35 mL/min; the short duration of IV use for acute VT termination is insufficient for NAPA to accumulate to clinically significant concentrations, and the pharmacokinetic concerns about NAPA apply only to patients on chronic oral procainamide where steady-state accumulation over weeks produces toxic NAPA levels
ANSWER: A
Rationale:
The critical pharmacokinetic issue with procainamide in renal impairment is NAPA accumulation. N-acetylprocainamide (NAPA) is formed by hepatic N-acetyltransferase 2 (NAT2) from procainamide and has predominantly Class III activity through IKr potassium channel blockade, without significant sodium channel blocking activity. NAPA is eliminated almost entirely by renal excretion, making its clearance directly proportional to CrCl. In a patient with CrCl of 35 mL/min, NAPA clearance is approximately half normal, and NAPA accumulates during procainamide infusion. The clinical consequence is progressive QTc prolongation from NAPA's IKr blockade ; a toxicity that can persist and worsen even after the procainamide infusion is stopped, because NAPA continues to accumulate from the remaining body stores of procainamide being converted to NAPA by NAT2. The QTc must be monitored throughout the infusion and for several hours after. NAPA plasma levels should be measured alongside procainamide levels. If the QTc exceeds 500 ms or rises more than 25 percent above baseline, the infusion should be stopped. Alternative agents (amiodarone, direct current cardioversion) should be strongly considered.
Option B: Option B is incorrect: while procainamide does have some renal elimination, the primary pharmacokinetic concern in renal impairment is NAPA accumulation through IKr blockade causing QTc prolongation, not parent drug accumulation causing QRS widening through sodium channel block.
Option C: Option C is incorrect: DILS develops after weeks to months of procainamide therapy, not within 48 to 72 hours of acute IV infusion; prophylactic hydroxychloroquine is not a recognized management strategy for acute IV procainamide administration.
Option D: Option D is incorrect: procainamide's volume of distribution is not significantly altered by uremic protein binding competition; the loading dose reduction is not standard practice for the stated reason; the primary concern is NAPA accumulation, not altered protein binding.
Option E: Option E is incorrect: NAPA accumulation can become clinically significant within hours of IV procainamide infusion in a patient with CrCl of 35 mL/min; this is not exclusively a chronic oral dosing concern; the claim that short IV use is safely immune to NAPA accumulation is incorrect and potentially dangerous in clinical practice.
8. A 77-year-old woman with atrial flutter and chronic heart failure (LVEF 35%) has been stable on digoxin 0.25 mg daily (serum level 1.1 ng/mL) and furosemide for two years. A cardiologist starts quinidine 200 mg three times daily for rhythm control of her flutter. One week later she presents with anorexia, nausea, and confusion. Her serum digoxin level is 2.6 ng/mL and her ECG shows accelerated junctional rhythm with 2:1 AV block. Which of the following best explains this event and the prescribing error?
A) Quinidine has displaced digoxin from skeletal muscle binding sites through competitive protein binding, rapidly shifting digoxin from the tissue compartment into the plasma compartment and raising the serum digoxin level; the 50 percent rise in digoxin level is expected and transient, resolving within 48 hours without dose adjustment
B) Quinidine's antimuscarinic properties have enhanced AV nodal conduction, allowing the atrial flutter to conduct faster and increasing the ventricular rate; the apparent digoxin toxicity is actually a hemodynamic consequence of the increased rate rather than true pharmacokinetic drug interaction
C) Quinidine has induced the hepatic CYP3A4 enzyme responsible for digoxin metabolism, paradoxically increasing digoxin clearance and lowering digoxin levels; the apparent elevated serum level reflects digoxin immunoassay cross-reactivity with quinidine metabolites rather than true digoxin accumulation
D) Quinidine's Class Ia IKr blockade has produced pharmacodynamic synergy with digoxin's vagotonic AV nodal slowing, creating additive AV nodal conduction block that is independent of digoxin serum concentrations; the digoxin level elevation is a coincidental laboratory finding unrelated to the clinical presentation
E) Quinidine inhibits P-glycoprotein (P-gp) transport in both the renal tubule and the biliary epithelium, substantially reducing digoxin elimination through these two major secretory pathways; this pharmacokinetic interaction typically raises serum digoxin concentrations by approximately 50 to 100 percent ; essentially doubling the effective digoxin exposure; the prescribing error was initiating quinidine without reducing the digoxin dose by approximately 50 percent and rechecking the digoxin level within one week; the digoxin dose must be halved immediately and toxicity managed
ANSWER: E
Rationale:
The quinidine-digoxin interaction is one of the most important and well-documented pharmacokinetic drug interactions in cardiology. Quinidine inhibits P-glycoprotein (P-gp), an efflux transporter that plays a major role in digoxin elimination through two routes: renal tubular secretion (where P-gp in the proximal tubule pumps digoxin from blood into tubular lumen for elimination) and biliary secretion (where P-gp in hepatocytes pumps digoxin from hepatocytes into bile for fecal elimination). When quinidine inhibits P-gp at both sites, digoxin elimination through these pathways is substantially reduced, and plasma digoxin concentrations typically rise by 50 to 100 percent ; effectively doubling. In this patient, the baseline digoxin level of 1.1 ng/mL has nearly tripled to 2.6 ng/mL, consistent with this interaction magnitude in a patient who also has reduced renal function from heart failure. The standard clinical approach when initiating quinidine in a digoxin-treated patient is to reduce the digoxin dose by approximately 50 percent prophylactically and recheck the level within one week.
Option A: Option A is incorrect: digoxin displacement from skeletal muscle tissue binding by quinidine does contribute to the interaction but is not the primary mechanism; the dominant mechanism is P-gp inhibition reducing renal and biliary digoxin elimination; the interaction is not transient and does not resolve without dose adjustment.
Option B: Option B is incorrect: the serum digoxin level of 2.6 ng/mL and the clinical presentation of anorexia, nausea, and confusion with AV block are consistent with genuine digoxin toxicity, not a rate consequence of quinidine's antimuscarinic properties.
Option C: Option C is incorrect: quinidine does not induce CYP3A4; digoxin immunoassay cross-reactivity with quinidine metabolites is not an established clinical phenomenon producing this magnitude of apparent digoxin elevation.
Option D: Option D is incorrect: the pharmacodynamic synergy between quinidine's IKr blockade and digoxin's vagotonic AV nodal slowing is not the primary explanation; the digoxin level is genuinely elevated from pharmacokinetic interaction through P-gp inhibition.
9. A 68-year-old man with paroxysmal AF and no structural heart disease (LVEF 62%) has a CrCl of 42 mL/min. His cardiologist appropriately discontinues flecainide because of QRS widening and switches to sotalol 80 mg twice daily ; the standard starting dose ; without adjusting for renal function. Two weeks later he collapses and is found in torsades de pointes. His QTc before the event was documented at 548 ms. Which of the following best explains this complication?
A) Sotalol is contraindicated in any patient with CrCl below 50 mL/min; the switch from flecainide to sotalol was an error because the same renal function concern that requires flecainide dose reduction makes sotalol uniformly dangerous in this CrCl range; amiodarone was the only appropriate alternative
B) Sotalol undergoes predominantly renal elimination as unchanged drug, with minimal hepatic metabolism; in a patient with CrCl of 42 mL/min, standard dosing of 80 mg twice daily produces substantially elevated sotalol plasma concentrations compared with patients with normal renal function; the resulting excessive IKr blockade prolonged the QTc to 548 ms, creating the substrate for TdP; sotalol can be used in moderate renal impairment but requires dose adjustment ; specifically 80 mg once daily (rather than twice daily) for CrCl of 30 to 60 mL/min, with in-hospital initiation and mandatory QTc monitoring
C) The TdP was caused by rebound Class Ic proarrhythmia from flecainide withdrawal; abrupt discontinuation of flecainide in a patient with chronic sodium channel occupancy produces a paradoxical upregulation of sodium channel density, creating a proarrhythmic substrate that, when combined with any potassium channel blocking drug, produces TdP within two weeks of flecainide discontinuation
D) The complication reflects a pharmacodynamic interaction between residual flecainide and sotalol; flecainide has a tissue half-life of three to four weeks in cardiac myocytes, producing slow-release sodium channel blockade that combines with sotalol's IKr blockade to produce a combined Class Ia-like effect with both QRS widening and QT prolongation causing TdP
E) The TdP reflects sotalol-induced hypokalemia through its beta-blocking properties; sotalol's non-selective beta-blockade activates the renin-angiotensin-aldosterone system, producing secondary aldosteronism and urinary potassium wasting; the resulting hypokalemia amplified IKr blockade and precipitated TdP independent of the sotalol plasma concentration
ANSWER: B
Rationale:
Sotalol is eliminated almost entirely by renal excretion as unchanged drug, with a renal clearance that is directly proportional to CrCl. In patients with normal renal function, the standard dose of 80 mg twice daily produces therapeutic plasma concentrations. In a patient with CrCl of 42 mL/min, the same dose produces substantially higher plasma concentrations because renal clearance is approximately 40 to 50 percent of normal, causing drug accumulation. Elevated sotalol concentrations produce excessive IKr blockade, progressively prolonging the QTc. The prescribing guidelines for sotalol specify that in patients with CrCl of 30 to 60 mL/min, the dosing interval should be extended to every 24 hours (80 mg once daily) rather than twice daily, and initiation must occur in a monitored hospital setting with mandatory QTc monitoring. The QTc of 548 ms ; substantially above the 500 ms threshold for TdP risk ; directly reflects the sotalol accumulation. This case illustrates that switching from one rhythm control agent to another requires the same attention to renal dose adjustment that applies to the first agent.
Option A: Option A is incorrect: sotalol is not uniformly contraindicated at CrCl below 50 mL/min; it can be used with dose interval adjustment (every 24 hours for CrCl 30 to 60 mL/min); amiodarone is an option but sotalol is not categorically excluded.
Option C: Option C is incorrect: flecainide withdrawal rebound proarrhythmia through sodium channel density upregulation is not an established clinical phenomenon; the mechanism described is pharmacologically fabricated.
Option D: Option D is incorrect: flecainide does not have a tissue half-life of three to four weeks in cardiac myocytes; its elimination half-life is approximately 12 to 27 hours and drug is effectively cleared within days of discontinuation; there is no established slow-release cardiac tissue compartment.
Option E: Option E is incorrect: sotalol's non-selective beta-blockade does not activate the renin-angiotensin-aldosterone system to produce pathological potassium wasting; beta-blockers may modestly affect renin release but do not produce secondary aldosteronism and significant hypokalemia; the TdP is from sotalol accumulation, not drug-induced hypokalemia.
10. A 38-year-old man is diagnosed with Brugada syndrome following resuscitation from ventricular fibrillation. Genetic testing confirms a loss-of-function SCN5A mutation. His electrophysiologist recommends ICD implantation, quinidine for pharmacological storm suppression, and strict avoidance of certain medications. The attending physician asks which Class I subclass might be safest to use if antiarrhythmic therapy is ever needed in this patient for a future atrial arrhythmia. Which of the following best answers this question?
A) Class Ib agents (lidocaine, mexiletine) are safe in Brugada syndrome because their fast-recovery kinetics preferentially target ischemic and inactivated channels rather than the normal sodium channels that are already reduced in Brugada; the fast unbinding prevents accumulation of block in the already-reduced sodium channel population
B) Class Ia agents (quinidine, procainamide, disopyramide) are the safest Class I subclass in Brugada syndrome because their concurrent IKr blockade prolongs repolarization and counteracts the shortened effective refractory period that underlies the Brugada arrhythmic mechanism; quinidine is actually a recognized treatment option for Brugada syndrome
C) Class Ic agents (flecainide, propafenone) are the safest Class I subclass in Brugada syndrome because they produce marked conduction slowing that eliminates the heterogeneous conduction responsible for the type 1 Brugada ECG pattern; their slow-recovery kinetics allow time for complete channel recovery between beats in normal epicardial cells
D) No Class I subclass is safe in Brugada syndrome; sodium channel blockade by any Class I agent further reduces already-impaired INa in a condition caused by loss-of-function sodium channel mutations, worsening the transmural voltage gradient in the right ventricular outflow tract that underlies the Brugada ECG pattern and VF risk; Class I agents are used as diagnostic provocative agents (ajmaline, flecainide, procainamide) to unmask type 1 Brugada pattern in suspected cases; they are contraindicated therapeutically in established Brugada syndrome
E) Class Ib agents are contraindicated but Class Ia and Ic agents can be used safely if the QRS duration is monitored; the key risk in Brugada syndrome is QRS widening above 120 ms, which can be avoided with low-dose Class I therapy and regular ECG monitoring; Class Ib agents are unsafe because their APD-shortening effect worsens the repolarization abnormality in right ventricular epicardium
ANSWER: D
Rationale:
Brugada syndrome is caused by loss-of-function mutations in SCN5A (as in this patient) or other genes affecting sodium channel function, resulting in reduced INa in the right ventricular outflow tract (RVOT) epicardium. The pathophysiological mechanism involves a transmural voltage gradient in the RVOT between the epicardium (with reduced INa and a prominent phase 1 notch from Ito) and the endocardium, creating the conditions for phase 2 re-entry and ventricular fibrillation. Any drug that further reduces INa ; including all Class I sodium channel blockers ; worsens this transmural voltage gradient, amplifies the ST-segment elevation, and increases the risk of VF. This is precisely why Class I agents (ajmaline, flecainide, and procainamide) are used as diagnostic provocative agents in the Brugada syndrome evaluation: sodium channel blockade unmasks the type 1 Brugada ECG pattern in patients with concealed disease. The same mechanism makes all Class I agents therapeutically contraindicated in established Brugada syndrome. The only exception is quinidine, which is recognized as a treatment option for Brugada syndrome ; not because of its sodium channel blocking properties, but because of its Ito-blocking activity (a transient outward potassium current) that reduces the phase 1 notch and normalizes the transmural voltage gradient.
Option A: Option A is incorrect: Class Ib agents are not safe in Brugada; even fast-recovery kinetics reduce INa during each action potential, worsening the transmural RVOT voltage gradient; the distinction between ischemic and normal channel populations does not protect Brugada patients from Class Ib sodium channel block.
Option B: Option B is incorrect: quinidine is recognized for Brugada syndrome not because of its sodium channel blocking properties or IKr blockade, but specifically because of its Ito blockade; the sodium channel blocking component of quinidine is a risk, not a benefit, in Brugada.
Option C: Option C is incorrect: Class Ic agents are among the most potent provocative agents for unmasking Brugada pattern; their slow-recovery kinetics produce maximal INa reduction, which is the exact mechanism of harm in Brugada.
Option E: Option E is incorrect: no Class I subclass is safe in Brugada regardless of QRS monitoring; the mechanism of harm is through reducing INa, not through QRS widening per se; QRS monitoring cannot prevent the pathophysiological worsening.
11. A 71-year-old man with paroxysmal atrial fibrillation, a prior inferior MI six years ago (LVEF 50%, small inferior scar), CKD stage 3 (CrCl 38 mL/min), and moderate persistent asthma (on inhaled corticosteroid and long-acting beta-agonist) requires rhythm control. His cardiologist systematically reviews all antiarrhythmic options. Which of the following correctly identifies the only broadly appropriate pharmacological rhythm control option and the reasoning that eliminates each alternative?
A) Sotalol is the most appropriate agent; dronedarone and flecainide are eliminated by structural disease, propafenone by asthma, and amiodarone's pulmonary toxicity risk is prohibitive in a patient with pre-existing asthma; sotalol can be used with a reduced dosing interval given the CrCl of 38 mL/min and in-hospital initiation with QTc monitoring
B) Dronedarone is the most appropriate agent; flecainide and propafenone are eliminated by structural disease and asthma respectively; procainamide and quinidine carry excessive proarrhythmic risk; sotalol requires careful renal dose adjustment; and amiodarone's long-term toxicity profile makes it a last resort; dronedarone has no structural disease contraindication at LVEF 50% and is renally excreted so no renal dose adjustment is needed
C) Amiodarone is the only broadly appropriate agent for this patient; flecainide and propafenone are contraindicated by prior MI structural disease (CAST principle); propafenone additionally carries bronchospasm risk from its beta-blocking properties in a patient with asthma; dronedarone is contraindicated in patients with prior MI and reduced ejection fraction below 55 percent or significant structural disease based on ANDROMEDA and PALLAS (Permanent Atrial fibrillation outcome Study using Dronedarone on top of standard therapy) trial data; sotalol requires in-hospital initiation, dose interval adjustment (every 24 hours at CrCl 30 to 60 mL/min), and careful QTc monitoring with moderate renal impairment making it a high-risk choice; amiodarone is hepatically cleared, has no renal dose adjustment requirement, no structural disease contraindication, and no bronchospasm risk, making it the appropriate selection despite its long-term toxicity monitoring requirements
D) Quinidine is the most appropriate agent; Class Ic agents are eliminated by structural disease, sotalol by renal concerns, dronedarone by structural disease, and amiodarone by the interaction risk with the patient's inhaled corticosteroid through CYP3A4 competition; quinidine as a Class Ia agent avoids all these concerns and requires only standard dose adjustments
E) No pharmacological rhythm control is appropriate for this patient given the combination of structural disease, renal impairment, and asthma; rate control alone with metoprolol (at reduced doses given his asthma) should be pursued, with rhythm control reconsidered only after the asthma is in complete remission and the renal function has stabilized above CrCl 50 mL/min
ANSWER: C
Rationale:
This question requires systematic elimination of rhythm control options in a complex patient with three comorbidities. Class Ic agents (flecainide, propafenone): both are contraindicated by the CAST principle in this patient with prior MI and ischemic structural disease regardless of current LVEF. Propafenone carries the additional contraindication of beta-blocking-mediated bronchospasm in a patient with moderate persistent asthma. Class Ia agents (quinidine, procainamide, disopyramide): while not subject to the CAST contraindication per se, these agents carry significant proarrhythmic risk (TdP from QT prolongation), procainamide has NAPA accumulation concerns with CrCl 38 mL/min, and none represents a preferred first-line option for AF rhythm control in current practice. Dronedarone: the ANDROMEDA trial demonstrated harm with dronedarone in patients with recently decompensated heart failure, and the PALLAS trial showed harm in permanent AF. More specifically, dronedarone is generally avoided in patients with significant structural heart disease including prior MI with any degree of ventricular dysfunction; LVEF 50% with documented ischemic scar creates enough concern to contraindicate dronedarone. Sotalol: renally eliminated, requires dose interval adjustment to 80 mg every 24 hours at CrCl 30 to 60 mL/min, and requires in-hospital initiation with continuous QTc monitoring. In a patient with asthma on a long-acting beta-agonist, sotalol's non-selective beta-blocking properties could also worsen bronchospasm. Amiodarone: hepatically cleared (no renal dose adjustment), no structural disease contraindication, no bronchospasm risk (does not block beta-2 receptors), and SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) demonstrated mortality neutrality in HFrEF. Its long-term toxicity profile (thyroid, pulmonary, hepatic, corneal) requires systematic monitoring but does not constitute a contraindication in this patient.
Option A: Option A is incorrect: sotalol remains problematic in this patient given the renal impairment requiring careful monitoring and its non-selective beta-blocking properties in a patient with active asthma on a beta-agonist; amiodarone is broader in safety profile.
Option B: Option B is incorrect: dronedarone is not appropriate in this patient with prior MI and structural disease; LVEF of 50% with ischemic scar is not a safe threshold for dronedarone; dronedarone is hepatically metabolized, not renally.
Option D: Option D is incorrect: quinidine carries significant proarrhythmic risk including TdP from QT prolongation and the quinidine-digoxin interaction if relevant; amiodarone does not interact meaningfully with inhaled corticosteroids through CYP3A4 competition in a clinically relevant way; the reasoning offered for amiodarone elimination is incorrect.
Option E: Option E is incorrect: amiodarone is an appropriate pharmacological rhythm control option in this patient; dismissing all pharmacological rhythm control is clinically incorrect and would leave the patient with symptomatic paroxysmal AF on rate control alone when a safe rhythm control option exists.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.